Caron's Addiction Research Symposium - October 25, 2019 - Wernersville, PA (5 CME)
- Registration Closed
Friday October 25, 2019| 8:00 am - 3:30 pm
Caron Treatment Centers
Chit Chat Auditorium
243 North Galen Hall Road
Wernersville, PA 19565
Showcasing the latest evidence-based practices, treatment models and cutting-edge research, Caron Treatment Centers’ 4th Annual Addiction Research Symposium bridges the gap between practice and research to improve the care of those suffering from substance use disorder. Leading experts in the field of Addiction Medicine from across the country will enlighten the audience about current and future treatment possibilities being explored by researchers today.
This event is appropriate for those who work in the field of Addiction Medicine, including psychiatrists, addiction medicine physicians, medical residents and students, medical researchers, nurse practitioners, physician assistants, and medical educators. Additionally, those who work with the addicted population, such as psychologists, behavioral health therapists, and addiction therapists, will find value in attending.
For information on topics and speakers, see the Schedule tab.
Registration Cancellation Policy:
Please email firstname.lastname@example.org for all cancellations and refund requests. There will be no refunds on cancellations received after Friday, October 11, 2019.
About Caron Treatment Centers
With 60 years in the field, Caron Treatment Centers operates lifesaving addiction and behavioral healthcare treatment. Caron is headquartered in Wernersville, Pennsylvania, with Ocean Drive and Caron Renaissance located in Palm Beach County, Florida. Caron has recovery centers in New England, Philadelphia and Washington, D.C., which offer community and recovery support. Caron’s Recovery Centers in Atlanta and New York City also offer pre- and post-treatment services. Caron has the most extensive continuum of care including teens, young adults, mid-life adults, older adults, chronic pain, executives, healthcare and legal professionals and families. Caron’s treatment is customized to meet the needs of individuals and families – with highly trained teams prepared to address co-occurring disorders. Caron offers an innovative approach to ongoing recovery care support for its patients and their families with online peer groups and other resources during the first year of transition following discharge. For more information on Caron, please visit www.caron.org.
2019 Caron's 4th Annual Addiction Research Symposium
Friday October 25, 2019 | 8:00 am - 3:30 pm
|8:00 am - 8:30 am||Welcome and Introduction|
|8:30 am - 9:30 am||Session 1: |
Therapeutic Uses and Neuropsychiatric Liabilities for Cannabinoids in the
Treatment of Chronic Pain
Daniel Morgan, PhD, Penn State College of Medicine
|9:30 am - 10:30 am||Session 2: |
The mu Opioid Receptor: Pivotal Element in Two Substance Use Disorders,
but Over-Looked by Most Clinicians
Charles O’Brien, MD, PhD, University of Pennsylvania
|10:30 am - 10:45 am||Break|
|10:45 am - 11:45 am||Session 3: |
The Use of an Animal Model to Understand Individual Vulnerability to
Opioid Use Disorder and Novel Avenues for Treatment
Sue Grigson, MS, PhD, Penn State College of Medicine
|11:45 am - 1:00 pm||Lunch and Networking|
|1:00 pm - 2:00 pm||Session 4: |
Decoding Circuit Signatures of Addiction Recovery: Opportunities for
Precision Medicine and Novel Interventions
Amit Etkin, MD, PhD, Stanford University
|2:00 pm - 3:00 pm||Session 5: |
Craving and Opioid Use: What We Think We Know and What We
Really Don't Know
Eric Strain, MD, John Hopkins University School of Medicine
|3:00 pm - 3:30 pm||Closing and Evaluations|
Presenter: Dr. Daniel Morgan
Topic: “Therapeutic Uses and Neuropsychiatric Liabilities for Cannabinoids in the Treatment of Chronic Pain”
1. List the therapeutic uses of cannabinoid-based medicines in the treatment of chronic pain.
2. Describe the limitations to the clinical use of cannabinoid-based medicines with an emphasis on addiction liability and the risk for schizophrenia.
3. Discuss the impact of recreational and medical cannabis use on the abuse of opioid drugs.
Presenter: Dr. Charles O’Brien
Topic: “The mu Opioid Receptor: Pivotal Element in Two Substance Use Disorders, but Over-Looked by Most Clinicians”
1. State the role of endogenous opioid system in alcohol use disorder.
2. Identify the role of drug cravings in relapse and maintenance of addiction.
3. Understand how family history of addictive disorders can be used as a guide to select relapse prevention medications.
4. List methods to detoxify opioid use disorder patients prior to naltrexone treatment.
5. Consider agonist versus antagonist for opioid use disorder.
6. Suggest the use of behavioral/psychotherapy in combination with medication.
Presenter: Dr. Sue Grigson
Topic: “Use of an Animal Model to Understand Individual Vulnerability to Opioid Use Disorder and Novel Avenues for Treatment”
1. Learn how devaluation of a natural reward predicts drug taking.
2. Understand the impact of individual differences in vulnerability to drug taking behavior.
3. Consider a novel and promising intervention whereby treatment with a glucagon-like peptide-1 (GLP-1) agonist reduces both cue- and drug-induced heroin seeking.
Presenter: Dr. Amit Etkin
Topic: “Decoding Circuit Signatures of Addiction Recovery: Opportunities for Precision Medicine and Novel Interventions”
1. Understand how machine learning can be applied to electroencephalography (EEG) data
2. Describe EEG signatures that predict recovery from addiction and their relationship to drugs of abuse
3. Describe EEG changes that track with the process of addiction recovery
Presenter: Dr. Eric Strain
Topic: “Craving and Opioid Use: What We Think We Know and What We Really Don't Know”
1. Identify at least two reasons there is renewed interest in the concept of craving.
2. Present at least three measures used to assess craving.
3. Describe the difference between craving as a moderator and craving as an endpoint in research.
AMA Accreditation Information
The American Society of Addiction Medicine designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Society of Addiction Medicine has been awarded the highest level of Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) as a provider of continuing medical education (CME) for physicians. Accreditation in the ACCME System seeks to assure the medical community and the public that ASAM delivers education that is relevant to clinicians’ needs, evidence-based, evaluated for its effectiveness, and independent of commercial influence.